Below The Knee | Market Signal

When Procedure Friction Disappears, Differentiation Matters More

UnitedHealthcare will eliminate prior authorization for roughly 1,700 procedure codes effective October 1—but wound care and limb salvage are conspicuously absent. The exemptions focus on outpatient orthopedic procedures, arthroscopy, certain diagnostics, and rehabilitation therapies. Core wound management (debridement, grafting) and vascular interventions remain subject to prior authorization across Medicare Advantage and D-SNP plans. The move signals UnitedHealthcare's confidence in high-approval-rate procedures, but preserves PA leverage where it matters most - complex, high-cost salvage decisions.

Capital is consolidating around surgical robotics and complex intervention. Enovis acquired eCential Robotics to compete in knee and shoulder surgery automation. Medtronic invested heavily in Cornerstone Robotics distribution and Pi-Cardia TAVR technology. Stryker launched an FDA-authorized app for Apple Vision Pro in the operating room. Medtronic's Q1 beat and guidance raise signal broad portfolio confidence in surgical intervention markets.

And the infrastructure story got worse.

ShinyHunters, an organized cybercriminal group, has systematically targeted medtech supply chain throughout 2026. Stryker hit earlier this year (thousands of employee devices wiped). Medtronic April 2026. Boston Scientific August 25. McKesson August 25 (same day as Boston Scientific). The group claims 284 million patient records from McKesson's oncology and medical-surgical units. $55 million ransom demand. Same methodology every time: voice phishing → compromised Okta SSO → access to Salesforce/Snowflake → data exfiltration.

This isn't isolated incident. This is systematic infrastructure attack on the medtech supply chain. Distribution, manufacturing, device makers — all exposed simultaneously.

Here's what differentiation looks like in this environment:

Abbott Esprit BTK received CE Mark for extended-length 76mm version, targeting chronic limb-threatening ischemia below the knee. Specific clinical positioning. BioLab Holdings acquired FastSkin, adding autologous wound care technology to its tissue restoration portfolio. Alternative to allografts. FibroBiologics secured U.S. patent on fibroblast-based wound healing therapy, strengthening IP position in cellular therapy space. Clyra Medical (BioLargo subsidiary) added third distribution channel through Spartan Medical for ViaCLYR wound irrigation, expanding government facility access.

Kane Biotech Q2 results: revyve commercialization underway but revenue only $8,143, net loss $834K, cash position $855K at quarter-end. Company entered non-exclusive distribution agreement with Ontario Medical Supply for Canadian expansion — lifeline for small-cap survival. Spectral AI presenting at H.C. Wainwright conference on DeepView wound diagnostics commercialization progress.

The story isn't complex cardio robotics or surgical precision systems. The story is small-cap specialists fighting for reimbursement clarity, distribution channels, and cash runway while infrastructure under systematic attack exposes concentration risk in medtech supply chain.

When friction disappears (prior auth removal), differentiation matters more. The winners are specialists with clinical positioning, IP protection, and distribution momentum. The losers are generalists exposed to supply chain concentration risk.

Here's the week.

We are 7 days away from IPAWS & Tissue Repair Summit in New Orleans. Below The Knee is the Official Market Intelligence Partner.

September 10–11 | The Ritz-Carlton, New Orleans, LA

ipawssummit.com →

Reimbursement | UnitedHealthcare to Drop Prior Authorization for Range of Conditions

UnitedHealthcare announced it will eliminate prior authorization requirements for a range of medical conditions, effective October 1. This policy shift could meaningfully reduce administrative barriers for wound care and vascular intervention procedures, potentially improving patient access to advanced therapies. For BTK-adjacent medtech companies, reduced prior auth burden may accelerate treatment initiation and improve reimbursement predictability across key product categories.

The BTK read: Prior auth removal is procedural tailwind for the entire category. Administrative friction reduction benefits wound care broadly, but biggest impact hits complex or specialized treatments where prior auth was most common. Watch for adoption curve and whether other insurers follow. This is macro category health signal, not a game-changer for specialists with clear reimbursement pathways. For companies like Kane Biotech fighting for adoption, easier access to treatment could help.

Market | BioLab Holdings Acquires FastSkin Autologous Wound Care Technology

BioLab Holdings has added FastSkin, an autologous wound care technology, to its tissue restoration portfolio. This acquisition expands BioLab's presence in the advanced wound care segment with a patient-derived biological approach to wound healing. The move signals continued consolidation in the skin substitute and tissue restoration space, where autologous technologies are gaining traction as alternatives to traditional allografts and xenografts.

The BTK read: Autologous wound care is the hedge against CAMP reimbursement compression. BioLab's FastSkin acquisition positions the company in the "patient's own cells" segment where reimbursement logic is different from off-the-shelf allografts. This is portfolio diversification away from traditional CAMP exposure. Track adoption rates to see if autologous approaches gain traction in SNFs and outpatient centers as traditional CAMP pricing pressures mount.

Market | Kane Biotech Q2 2026 Financial Results

Kane Biotech's Q2 2026 results show the company is in transition to a focused human wound-care business, with revyve commercialization underway but revenue falling to just $8,143, while gross profit turned positive at $1,444. The bigger concern is financial: net loss widened to $834K and cash was only $855K at quarter-end, making near-term commercialization of revyve and additional financing critical. Kane Biotech signed Ontario Medical Supply Inc. as exclusive reseller, gaining access to Ontario Health atHome formulary serving 680,000+ patients annually, representing a lifeline for Canadian commercialization ahead of potential capital raise.

The BTK read: Kane Biotech's cash crunch is real. $855K at quarter-end means runway is measured in months, not quarters. The Ontario distributor agreement is strategically smart (wound care is 40-50% of home-care nursing visits in Ontario), but it's also the company betting its survival on Canadian expansion before financing options narrow. Watch for announcements on capital raise or strategic partnership. If revyve traction accelerates in Canada, it could improve fundraising narrative. If not, dilution or asset sale likely.

Regulatory | FibroBiologics Secures US Patent for Fibroblast-Based Wound Healing Therapy

FibroBiologics has been issued a new U.S. patent covering the therapeutic use of fibroblasts in wound healing, strengthening its IP position in the cellular therapy space. This patent reinforces the company's competitive moat as fibroblast-based biologics gain traction as a next-generation approach to chronic and complex wound management.

The BTK read: Patent issuance is IP moat-building moment. FibroBiologics' fibroblast approach is mechanistically differentiated from allografts and cellular matrix products. As CAMP reimbursement tightens, IP-protected differentiated approaches attract capital and clinical adoption. This is proof-of-concept that cellular therapy space rewards clinical validation + IP protection. Track for clinical trial progress and potential licensing or partnership discussions.

Regulatory | Abbott Esprit BTK 76-mm Gains CE Mark for CLTI Treatment

Abbott received CE Mark approval for an extended-length (76-mm) version of its Esprit below-the-knee resorbable scaffold system, targeting chronic limb-threatening ischemia. This represents a significant product expansion for Abbott's vascular intervention portfolio, offering physicians a longer treatment option for severe peripheral artery disease below the knee.

The BTK read: Abbott's 76mm extension is specific clinical positioning. Longer scaffolds enable treatment of longer lesions in BTK territory, which is exactly the limb salvage sweet spot. CE Mark enables European launch and establishes clinical validation before potential US expansion. Watch for real-world outcome data and adoption in PAD referral centers. This is the product expansion template: identified clinical need (longer CLTI lesions), cleared solution, defined patient population.

Market | Terumo Neuro WISE Study Publications: Zero Rebleeds After WEB Treatment

Terumo Neuro announced two peer-reviewed WISE study publications reporting 0% new bleeds or rebleeds through one year post-WEB implantation in both ruptured and unruptured intracranial aneurysm cohorts. The largest prospective WEB pooled dataset strengthens clinical evidence for neurovascular intervention outcomes.

The BTK read: WEB (WebMD Embolization) is intracranial aneurysm treatment, not directly BTK limb salvage. But the pattern matters: strong clinical data in peer-reviewed journals driving adoption in neurovascular space. This is template for how specialists with clear clinical evidence outperform generalists. Similar pattern we're seeing in autologous wound care and fibroblast-based therapies.

Market | Spectral AI to Present H.C. Wainwright Conference on DeepView Commercialization

Spectral AI announced CEO Vincent Capone and CFO David McGuire are scheduled to present at H.C. Wainwright's 28th Annual Global Investment Conference September 14-16, 2026 in New York City. The company will present growth strategy and commercialization progress for its DeepView System, which combines multispectral imaging with AI algorithm to assess healing potential of burn wounds.

The BTK read: Spectral AI's investor conference presentation is commercialization signal. DeepView's FDA De Novo clearance gave them proprietary regulatory pathway in wound diagnostics. H.C. Wainwright conference attracts growth-stage medtech capital. Watch for investor interest and whether partnership or funding announcements follow. AI-powered wound assessment is exactly the infrastructure play that attracts capital when reimbursement and clinical adoption momentum align.

Investment | Enovis Enters Binding Offer to Acquire eCential Robotics for €155M

Enovis announced a binding offer to acquire eCential Robotics, expanding its ASTRA enabling technology platform with surgical robotics capabilities. The €155M upfront enterprise value acquisition (plus up to €35M in contingent consideration) is expected to close by year-end 2026. eCential previously developed J&J's Velys Spine robot, giving Enovis a credible foundation to compete with Stryker, Zimmer Biomet, and Smith & Nephew in surgical robotics space.

The BTK read: Enovis eCential acquisition is consolidation around surgical robotics. While orthopedic rather than wound care, the pattern matters: large-cap medtech deploying capital toward procedural precision systems and surgical automation. This is where medtech energy is concentrating. Smaller wound care players can't compete in this space. They need differentiation instead.

Investment | Medtronic Announces $700M Cornerstone Robotics Investment Partnership

Medtronic announced a $700M strategic investment in Cornerstone Robotics gaining distribution rights for the Sentire surgical system in select non-U.S. markets. Sentire complements Medtronic's Hugo robotic-assisted surgery platform in minimally invasive procedures.

The BTK read: Medtronic's Cornerstone deal is portfolio expansion in surgical robotics. Distribution rights model differs from full acquisition (Enovis approach), but signal is same: surgical automation infrastructure matters. Medtronic also invested $80M in Pi-Cardia (complex TAVR leaflet modification technology) same week. Dual investments signal broad confidence in complex intervention market despite reimbursement pressure.

Investment | Medtronic Invests up to $80M in Pi-Cardia with Acquisition Option

Medtronic announced an up-to-$80M strategic investment in Pi-Cardia, an Israeli medtech firm developing leaflet modification technology for complex TAVR. Medtronic gains exclusive global distribution rights to the FDA-cleared ShortCut device in 2027 and holds a $210M acquisition option upon milestone achievement.

The BTK read: Pi-Cardia investment is portfolio play on complex vascular intervention. TAVR (transcatheter aortic valve replacement) is high-volume procedure where complex anatomy creates clinical need for specialized solutions. This is adjacent-market expansion by large-cap medtech, not core to wound care but signals capital confidence in vascular intervention category.

Financial | Medtronic Q1 FY27 Earnings Beat, Raises Organic Growth Guidance

Medtronic reported Q1 FY27 non-GAAP EPS of $1.45 vs. $1.39 expected and revenue of $9.8B, up 13.7% organically, prompting 50 bps raise in FY27 organic growth guidance to 7.25-7.75%. Cardiovascular, neuroscience, and Medical Surgical divisions drove broad-based portfolio strength.

The BTK read: Medtronic's beat and raise is large-cap portfolio confidence. Cardiovascular and vascular intervention strength is visible in guidance confidence. For BTK medtech, Medtronic's trajectory shows surgical intervention market health. But this is complex procedure and robotics story, not limb salvage and wound care story.

Regulatory | Stryker Launches FDA-Authorized Surgical App for Apple Vision Pro

Stryker has introduced an FDA-authorized surgical application designed for Apple Vision Pro, bringing mixed-reality visualization into the operating room. The app enables surgeons to view 3D imaging and patient data during procedures, potentially enhancing precision in complex surgeries.

The BTK read: Stryker's Apple Vision Pro app is intraop guidance infrastructure play. Mixed-reality visualization for surgical precision is exactly where medtech is headed. While not BTK-specific, this is signal of how large-cap medtech is building procedural precision layers into their platforms. Smaller wound care and limb salvage players aren't competing at this level.

Market | McKesson Confirms Cybersecurity Incident Amid Systematic Wave of Attacks

McKesson has confirmed a cybersecurity incident after ShinyHunters, an organized cybercriminal group, claimed to have stolen 284 million patient records. The breach involved unauthorized access to third-party applications affecting McKesson's oncology and medical-surgical business units. McKesson discovered the incident on August 25, 2026. The ShinyHunters group claims approximately 1 terabyte of data was exfiltrated between August 21 and August 25 and is demanding over $55 million in ransom.

This is part of a systematic wave of medtech supply chain attacks throughout 2026. Stryker experienced a similar cyberattack earlier this year (employee devices remotely wiped). Medtronic hit in April. Boston Scientific on August 25 (same day as McKesson). Abbott, iRhythm, Cook Medical, CareCloud, and CenterPoint Health all victims of ShinyHunters or similar groups. The methodology is consistent: voice phishing → compromised Okta SSO → access to Salesforce/Snowflake → data exfiltration.

The BTK read: This isn't isolated incident. This is systematic infrastructure attack on medtech supply chain. McKesson's size (major pharmaceutical and medical supplies distributor underpinning wound care product delivery across healthcare system) makes this breach material risk. The pattern across Stryker, Medtronic, Boston Scientific, and McKesson reveals structural vulnerability in medtech infrastructure. For wound care and vascular intervention supply chain, this is systemic risk signal. Hospitals and providers should evaluate vendor diversification and backup strategies. Medtech companies should assume supply chain concentration risk is now strategic vulnerability.

September 10–11 | New Orleans, LA — IPAWS & Tissue Repair Summit (Kernexus) — The Ritz-Carlton (BTK Official Market Intelligence Partner)

September 14–16 | Louisville, KY — NAWCO HEAL Conference 2026

September 23–27 | Kuala Lumpur, Malaysia — WUWHS 2026 – World Union of Wound Healing Societies Congress — Kuala Lumpur Convention Centre

October 1–4 | Bengaluru, India — DFSICON 2026 — Hilton Garden Inn Bengaluru, Embassy Manyata Business Park

October 8–10 | New Delhi, India — ASVS–VSICON 2026 — Pullman & Novotel New Delhi Aerocity

October 15–18 | Las Vegas, NV — SAWC Fall 2026 — Caesars Palace

October 22–24 | Anaheim, CA — DFCon 2026 — JW Marriott

November 6 | Virtual — WoundCon Fall 2026

Early December (dates TBD) | San Antonio, TX — DFUpdate 2026 (ALPS)

December 9–12 | Phoenix, AZ — Desert Foot, Multi-Disciplinary Limb Salvage & Wound Care Conference

Not subscribed? newsletter.belowtheknee.co. Forward this to one person in your network who works in this space.

See you at IPAWS,

-Scott